{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:15:23Z","timestamp":1791918923872,"version":"4.3.4"},"reference-count":40,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported though remain poorly understood. Here, we analyze longitudinal tumor samples from 11 patients with disease progression while receiving venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in\u00a0vitro resistance to venetoclax at the posttreatment time point. We found the previously described acquired BCL2-G101V mutation in only 4 of 11 patients, with 2 patients showing a very low variant allele fraction (0.03%-4.68%). Whole-exome sequencing revealed acquired loss(8p) in 4 of 11 patients, of which 2 patients also had gain (1q21.2-21.3) in the same cells affecting the MCL1 gene. In\u00a0vitro experiments showed that CLL cells from the 4 patients with loss(8p) were more resistant to venetoclax than cells from those without it, with the cells from 2 patients also carrying gain (1q21.2-21.3) showing increased sensitivity to MCL1 inhibition. Progression samples with gain (1q21.2-21.3) were more susceptible to the combination of MCL1 inhibitor and venetoclax. Differential gene expression analysis comparing bulk RNA sequencing data from pretreatment and progression time points of all patients showed upregulation of proliferation, B-cell receptor (BCR), and NF-\u03baB gene sets including MAPK genes. Cells from progression time points demonstrated upregulation of surface immunoglobulin M and higher pERK levels compared with those from the preprogression time point, suggesting an upregulation of BCR signaling that activates the MAPK pathway. Overall, our data suggest several mechanisms of acquired resistance to venetoclax in CLL that could pave the way for rationally designed combination treatments for patients with venetoclax-resistant CLL.<\/jats:p>","DOI":"10.1182\/blood.2022016600","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T19:39:39Z","timestamp":1683315579000},"page":"421-433","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4656-8454","authenticated-orcid":false,"given":"Jasneet Kaur","family":"Khalsa","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Cha","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3226-7642","authenticated-orcid":false,"given":"Filippo","family":"Utro","sequence":"additional","affiliation":[{"name":"3IBM Research, Yorktown Heights, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishath","family":"Naeem","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishwarya","family":"Murali","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Kuang","sequence":"additional","affiliation":[{"name":"4Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0062-9389","authenticated-orcid":false,"given":"Kevin","family":"Vasquez","sequence":"additional","affiliation":[{"name":"4Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-6507","authenticated-orcid":false,"given":"Svitlana","family":"Tyekucheva","sequence":"additional","affiliation":[{"name":"5Department of Data Sciences, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey M.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-7974","authenticated-orcid":false,"given":"Lauren","family":"Veronese","sequence":"additional","affiliation":[{"name":"6Service de Cytog\u00e9n\u00e9tique M\u00e9dicale, CHU Clermont-Ferrand, Clermont-Ferrand, France"},{"name":"7EA7453 CHELTER, Universit\u00e9 Clermont Auvergne, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Guieze","sequence":"additional","affiliation":[{"name":"7EA7453 CHELTER, Universit\u00e9 Clermont Auvergne, Clermont-Ferrand, France"},{"name":"8Service d\u2019H\u00e9matologie clinique et th\u00e9rapie cellulaire, CHU Clermont-Ferrand, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3325-9874","authenticated-orcid":false,"given":"Binu Kandathilparambil","family":"Sasi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixu","family":"Wang","sequence":"additional","affiliation":[{"name":"5Department of Data Sciences, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-3476","authenticated-orcid":false,"given":"John-Hanson","family":"Machado","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Bai","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Alasfour","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1567-9090","authenticated-orcid":false,"given":"Kahn","family":"Rhrissorrakrai","sequence":"additional","affiliation":[{"name":"3IBM Research, Yorktown Heights, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaya","family":"Levovitz","sequence":"additional","affiliation":[{"name":"3IBM Research, Yorktown Heights, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Danysh","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Slowik","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel A.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"9Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cloud P.","family":"Paweletz","sequence":"additional","affiliation":[{"name":"4Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignaty","family":"Leshchiner","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmi","family":"Parida","sequence":"additional","affiliation":[{"name":"3IBM Research, Yorktown Heights, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Getz","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"},{"name":"10Cancer Center, Massachusetts General Hospital, Boston, MA"},{"name":"11Department of Pathology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"},{"name":"9Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2023080315202917600_bib1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/bloodadvances.2020003423","article-title":"Overcoming resistance to targeted therapies in chronic lymphocytic leukemia","volume":"5","author":"Skanland","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2023080315202917600_bib2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"2023080315202917600_bib3","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2023080315202917600_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2023080315202917600_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"24","key":"2023080315202917600_bib6","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/blood.2019003722","article-title":"Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/PLCG2 mutations","volume":"135","author":"Lucas","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2023080315202917600_bib7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"key":"2023080315202917600_bib8","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3389\/fonc.2020.00894","article-title":"Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents","volume":"10","author":"Sedlarikova","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"2023080315202917600_bib9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat Commun"},{"issue":"20","key":"2023080315202917600_bib10","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2022016040","article-title":"Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy","volume":"140","author":"Thijssen","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2023080315202917600_bib11","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2023080315202917600_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Guieze","year":"2019","journal-title":"Cancer Cell"},{"issue":"10","key":"2023080315202917600_bib13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"7574","key":"2023080315202917600_bib14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"3","key":"2023080315202917600_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"7484","key":"2023080315202917600_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"issue":"1","key":"2023080315202917600_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"9","key":"2023080315202917600_bib18","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/ng.3343","article-title":"Paired exome analysis of Barrett's esophagus and adenocarcinoma","volume":"47","author":"Stachler","year":"2015","journal-title":"Nat Genet"},{"issue":"5","key":"2023080315202917600_bib19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nbt.2203","article-title":"Absolute quantification of somatic DNA alterations in human cancer","volume":"30","author":"Carter","year":"2012","journal-title":"Nat Biotechnol"},{"key":"2023080315202917600_bib20","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"issue":"4","key":"2023080315202917600_bib21","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol"},{"key":"2023080315202917600_bib22","doi-asserted-by":"publisher","DOI":"10.1101\/508127","article-title":"Comprehensive analysis of tumour initiation, spatial and temporal progression under multiple lines of treatment","author":"Leshchiner","year":"16  2019","journal-title":"bioRxiv"},{"issue":"suppl 5","key":"2023080315202917600_bib23","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s12864-021-07660-9","article-title":"A common methodological phylogenomics framework for intra-patient heteroplasmies to infer SARS-CoV-2 sublineages and tumor clones","volume":"22","author":"Utro","year":"2021","journal-title":"BMC Genomics"},{"issue":"2","key":"2023080315202917600_bib24","doi-asserted-by":"crossref","first-page":"E47","DOI":"10.1002\/ajh.26411","article-title":"Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy","volume":"97","author":"Popovic","year":"2022","journal-title":"Am J Hematol"},{"issue":"12","key":"2023080315202917600_bib25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"2023080315202917600_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13148-018-0570-4","article-title":"Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma","volume":"10","author":"Li","year":"2018","journal-title":"Clin Epigenetics"},{"key":"2023080315202917600_bib27","doi-asserted-by":"crossref","first-page":"600227","DOI":"10.3389\/fgene.2020.600227","article-title":"CDK6 is a potential prognostic biomarker in acute myeloid leukemia","volume":"11","author":"Liu","year":"2020","journal-title":"Front Genet"},{"issue":"suppl 1","key":"2023080315202917600_bib28","article-title":"Wnt5a induces ROR1 to interact Grb2 to enhance Ras activation in chronic lymphocytic leukemia [abstract]","volume":"138","author":"Hasan","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2023080315202917600_bib29","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41375-022-01543-y","article-title":"High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia","volume":"36","author":"Ghia","year":"2022","journal-title":"Leukemia"},{"issue":"43","key":"2023080315202917600_bib30","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl\u00a0Acad Sci U S A"},{"issue":"3","key":"2023080315202917600_bib31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"issue":"10","key":"2023080315202917600_bib32","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1158\/0008-5472.CAN-11-3605","article-title":"Activation of Ras\/PI3K\/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells","volume":"72","author":"Tsai","year":"2012","journal-title":"Cancer Res"},{"issue":"5","key":"2023080315202917600_bib33","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3324\/haematol.2019.217307","article-title":"Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription","volume":"105","author":"Edelmann","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"2023080315202917600_bib34","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4161\/cc.8.5.7887","article-title":"REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells","volume":"8","author":"Chang","year":"2009","journal-title":"Cell Cycle"},{"issue":"14","key":"2023080315202917600_bib35","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-11-2342","article-title":"Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia","volume":"18","author":"Brown","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2023080315202917600_bib36","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1080\/15384047.2015.1046025","article-title":"8p deletion is strongly linked to poor prognosis in breast cancer","volume":"16","author":"Lebok","year":"2015","journal-title":"Cancer Biol Ther"},{"issue":"suppl 1","key":"2023080315202917600_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-142655","article-title":"Activation of the ERK pathway drives acquired resistance to venetoclax in MM cell models [abstract]","volume":"136","author":"Chakraborty","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2023080315202917600_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"43","key":"2023080315202917600_bib39","doi-asserted-by":"crossref","first-page":"70000","DOI":"10.18632\/oncotarget.12132","article-title":"Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells","volume":"7","author":"Bodo","year":"2016","journal-title":"Oncotarget"},{"issue":"25","key":"2023080315202917600_bib40","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2015-10-675009","article-title":"BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199","volume":"127","author":"Bojarczuk","year":"2016","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/5\/421\/2067479\/blood_bld-2022-016600-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/5\/421\/2067479\/blood_bld-2022-016600-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T15:21:13Z","timestamp":1691076073000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/5\/421\/495676\/Genetic-events-associated-with-venetoclax"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,8,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022016600","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]}}}